Insulet Co. (NASDAQ:PODD) Shares Acquired by Swedbank AB

Swedbank AB increased its stake in shares of Insulet Co. (NASDAQ:PODD) by 152.9% in the 4th quarter, Holdings Channel reports. The firm owned 53,688 shares of the medical instruments supplier’s stock after purchasing an additional 32,456 shares during the period. Swedbank AB’s holdings in Insulet were worth $14,016,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baillie Gifford & Co. lifted its position in shares of Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after acquiring an additional 389,639 shares in the last quarter. Geode Capital Management LLC raised its stake in Insulet by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after purchasing an additional 22,850 shares during the last quarter. Westfield Capital Management Co. LP lifted its holdings in Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after purchasing an additional 163,388 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after purchasing an additional 193,839 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Insulet by 0.9% in the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after buying an additional 3,113 shares during the last quarter.

Insulet Trading Down 0.6 %

Shares of NASDAQ PODD opened at $278.38 on Friday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $19.53 billion, a PE ratio of 47.67, a PEG ratio of 3.48 and a beta of 1.22. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $286.39. The stock has a fifty day simple moving average of $268.69 and a 200-day simple moving average of $237.96.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. During the same period in the prior year, the firm earned $0.71 earnings per share. On average, equities analysts forecast that Insulet Co. will post 3.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on PODD shares. Morgan Stanley upped their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. BTIG Research lifted their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Finally, Canaccord Genuity Group upped their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a report on Monday, December 9th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $272.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.